Filing Flows › Healthpeak Properties (DOC) › Stock forecast & fair value
Healthpeak Properties (DOC) stock forecast and fair value
Healthpeak Properties (DOC) trades at $20.26. 19 analysts' median price target is $22.00 (+9%), from $17.00 to $29.00. Across 20 valuation methods the middle fair value is $22.11 (+9%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| P/E vs peers | $10.24 | $14.09 | $19.04 | -30% |
| P/E vs peers, weighted | $13.29 | $18.73 | $38.49 | -8% |
| P/E vs peers, matched | $10.38 | $13.87 | $18.16 | -32% |
| P/E vs peers, growth-adjusted | $8.64 | $14.59 | $24.63 | -28% |
| EV/Sales vs peers | $0.79 | $22.11 | $33.79 | +9% |
| EV/Sales vs peers, weighted | $21.64 | $35.20 | $45.26 | +74% |
| EV/Sales vs peers, matched | $5.36 | $29.43 | $36.19 | +45% |
| Residual income | $9.62 | $9.99 | $10.38 | -51% |
| P/FFO vs REIT peers | $23.72 | $28.27 | $40.31 | +40% |
| P/FFO vs REIT peers, weighted | $27.99 | $36.87 | $51.37 | +82% |
Healthpeak Properties' latest quarter
Healthpeak Properties, Q3 2026: revenue $821M (+16% year over year), operating margin 3.1%, net earnings $17.3M, operating cash flow $354M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for DOC stock?
The median of 19 analysts' 12-month targets is $22.00, +9% from $20.26; the range is $17.00 to $29.00. The average rating is buy.
What is Healthpeak Properties' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $8.37 and $36.87, with a middle value of $22.11 against a price of $20.26. Each method's assumptions are on the page.
Does Healthpeak Properties usually beat earnings estimates?
It beat the consensus EPS estimate in 80% of the quarters on record.
Is DOC stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.